🧬 Weekly Immunology Breakthroughs: Adolescent Psoriasis, PsA Joint Protection, GCA Milestone & Biosimilar Cost Savings
🔥 Stay informed with the most critical updates in Immunology—from pivotal clinical trials to regulatory approvals and market-shifting biosimilar developments shaping the future of autoimmune and inflammatory care.
🗞️ This week’s headlines: 💊 Icotrokinra Clears 75% of Teens with Plaque Psoriasis in Phase 3 Trial
🦴 Tremfya Becomes First IL-23 Inhibitor to Halt Joint Damage in Psoriatic Arthritis
✅ RINVOQ Approved in EU for Giant Cell Arteritis—First Oral JAK for GCA
💶 Samsung Bioepis Forecasts €526M in EU Savings with Stelara Biosimilar Pyzchiva
📢 Stay Ahead in Immunology Research!
✅ Like, share, and subscribe for weekly updates on autoimmune and inflammatory breakthroughs
#Immunology #AutoimmuneDiseases #Psoriasis #PsoriaticArthritis #GiantCellArteritis #JAKInhibitors #Biosimilars #ClinicalTrials #LucidQuest #HealthcareInnovation #InflammatoryDiseases #Dermatology #Rheumatology #HealthEconomics